Video Reports

Thomas Marron, MD, PhD, assistant professor of medicine, hematology, and medical oncology at Mount Sinai Hospital, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.  

Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco and director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center, compares the roles of immunotherapy versus dabrafenib (Tafinlar) plus trametinib (Mekinist) targeted therapy combinations in patients with advanced melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Jason J. Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the treatment landscape of metastatic melanoma.